Sanofi: begins licensing agreement with Innate Pharma

(CercleFinance.com) - Innate Pharma announces the expiry of the waiting period provided for by US law, and therefore the entry into force of the agreement granting Sanofi an exclusive license for the multi-specific NK cell engaging antibody program targeting B7H3.


Sanofi has also acquired an option to add up to two additional targets from Innate's ANKET platform. Following the selection of each drug candidate, it will be responsible for the development, manufacturing and commercialisation of the products.

Under the terms of the agreement, Innate will receive an upfront payment of 25 million euros and up to 1.35 billion euros in milestone payments based on the achievement of targets, as well as royalties on potential net sales.


Copyright (c) 2023 CercleFinance.com. All rights reserved.